Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 ALPMF | Healthcare | $17.32 | 1.03K | $30.43B | 12.54 | 2.88% | Hold |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ALPMF | Astellas Pharma | 17.32 | 5.49 | 46.43% |
| Name | Price | % Change | |
|---|---|---|---|
| ALPMF | $17.32 | +46.43% |
Astellas Pharma ($ALPMF) announced an update on their ongoing clinical study. Study Overview: Astellas Pharma is studying whether fezolinetant can reduce moderate to severe hot flashes in Indian women going
Astellas Pharma (ALPMF) is scheduled to report 1st quarter earnings on 08/05/2026, before the market opens. Regarding Q1 estimates, Wall Street analysts expect Astellas Pharma to post earnings of Yen54.10
Astellas Pharma ($ALPMF) announced an update on their ongoing clinical study. Astellas Pharma Inc. (ALPMF) has terminated an early-stage study called “An Open-label Phase 1 Study of ASP4396 in Participants
Sangamo Therapeutics (SGMO) announced that it has commenced voluntary Chapter 11 bankruptcy reorganization proceedings and entered into separate “stalking horse” asset sale agreements with Eli Lilly (LLY) and Astellas Pharma
Astellas Pharma ($ALPMF) announced an update on their ongoing clinical study. The Japan Post-Marketing Surveillance – Specified Drug Use-results Survey for Peficitinib tracks how Astellas Pharma’s rheumatoid arthritis drug performs
Astellas Pharma ($ALPMF), Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Symbiotic-GU-06 is an early-stage study run by Pfizer and Astellas Pharma Inc. It aims to test
An update from Astellas Pharma ( ($JP:4503) ) is now available. Astellas Pharma announced that outside director Dr. Andreas Busch resigned from the board effective May 29, 2026, prompting the
The latest update is out from Astellas Pharma ( ($JP:4503) ). Astellas Pharma has unveiled CSP2026, a five-year corporate strategic plan for fiscal 2026–2030 aimed at delivering faster value for
Astellas Pharma ( ($JP:4503) ) has issued an update. Astellas Pharma has resolved to continue its performance-linked stock compensation scheme for corporate executives and a performance-linked stock delivery scheme for
The latest announcement is out from Astellas Pharma ( ($JP:4503) ). Astellas Pharma has approved the implementation details of a performance-linked stock compensation plan for fiscal 2026, continuing its medium-
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| ALPMF | Feb 8, 2027TBA | $30.43B | $0.38 | $3.86B | 0.03 | 12.54 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
